List prices for branded pharmaceutical products in the United States increased 159% between 2007 and 2018, an average of 9.1% per year, according to a study reported this week in JAMA. List prices represent the manufacturers’ price to wholesalers or direct purchasers, but do not account for discounts. Net prices for branded pharmaceutical products, which represent per unit revenue after all discounts and manufacturer concessions, increased 60% over the period, or an average 4.5% per year, the study found.  

Related News Articles

Headline
Four drugs used in hospitals for years increased their prices between 525% and 1,644% after receiving formal approval through the Food and Drug Administration’…
Headline
The Food and Drug Administration today approved the first generic albuterol sulfate inhaler to treat and prevent bronchospasms in patients with asthma or…
Headline
The Food and Drug Administration today released the first phase of its searchable Purple Book database, which includes all FDA-approved biosimilar and…
Headline
The House Ways and Means Health Subcommittee yesterday held a hearing on proposals to lower drug prices and promote new cures.  Witness Ge Bai, an…
Headline
The Campaign for Sustainable Rx Pricing today launched an ad campaign calling for Congress to pass bipartisan legislation to “hold Big Pharma accountable…
Blog
Another day, another misleading PhRMA-funded study that attempts to deflect blame for a growing crisis of their own making – the skyrocketing cost of…